Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1972 1
1973 2
1974 1
1977 2
1980 1
1981 1
1985 3
1986 1
1988 1
1991 1
1992 1
1993 2
1996 1
1997 1
2002 3
2003 1
2005 4
2006 4
2007 2
2008 1
2009 3
2010 2
2011 3
2012 4
2013 3
2014 1
2015 2
2016 1
2017 2
2018 2
2019 3
2020 4
2021 5
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Paranasal Sinus Squamous Cell Carcinoma"
Page 1
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL. Cohen EEW, et al. J Immunother Cancer. 2019 Jul 15;7(1):184. doi: 10.1186/s40425-019-0662-5. J Immunother Cancer. 2019. PMID: 31307547 Free PMC article. Clinical Trial.
Improvement in outcomes are needed for patients with recurrent and or metastatic squamous cell carcinoma of the head and neck (HNSCC). In 2016, the US Food and Drug Administration (FDA) granted the first immunotherapeutic approvals - the anti-PD-1 immu …
Improvement in outcomes are needed for patients with recurrent and or metastatic squamous cell carcinoma of the …
Paranasal sinus cancer.
Jégoux F, Métreau A, Louvel G, Bedfert C. Jégoux F, et al. Eur Ann Otorhinolaryngol Head Neck Dis. 2013 Dec;130(6):327-35. doi: 10.1016/j.anorl.2012.07.007. Epub 2013 Mar 21. Eur Ann Otorhinolaryngol Head Neck Dis. 2013. PMID: 23523040 Free article. Review.
Paranasal sinus cancers are rare, aggressive tumours that are usually diagnosed at an advanced stage. ...Tumours are stage T3-T4 in two-thirds of cases and are associated with cervical lymph node involvement in 10% of squamous cell carcinomas and 4% of …
Paranasal sinus cancers are rare, aggressive tumours that are usually diagnosed at an advanced stage. ...Tumours are stage T3- …
Sinonasal cancers treatments: state of the art.
Ferrari M, Orlandi E, Bossi P. Ferrari M, et al. Curr Opin Oncol. 2021 May 1;33(3):196-205. doi: 10.1097/CCO.0000000000000726. Curr Opin Oncol. 2021. PMID: 33756515 Free PMC article. Review.
Prognostic value of the margin status and management of the nodal basin and recurrent sinonasal tumors are far from being fully elucidated. Most promising surgical technologies are surgical navigation, optical imaging, and radiofrequency-aided ablation. ...
Prognostic value of the margin status and management of the nodal basin and recurrent sinonasal tumors are far from being fully eluci …
Cetuximab and paclitaxel combination therapy for recurrent basaloid squamous cell carcinoma in the ethmoid sinus.
Koyama S, Fujiwara K, Morisaki T, Fujii T, Nakamura Y, Fukuhara T, Takeuchi H. Koyama S, et al. Auris Nasus Larynx. 2021 Dec;48(6):1189-1192. doi: 10.1016/j.anl.2020.07.002. Epub 2020 Jul 16. Auris Nasus Larynx. 2021. PMID: 32684403
Basaloid squamous cell carcinoma (BSCC), a histologically distinctive variant of squamous cell carcinoma comprising basal cell carcinoma and squamous cell carcinoma, is aggressive and shows a poor progno …
Basaloid squamous cell carcinoma (BSCC), a histologically distinctive variant of squamous cell carcino …
Induction chemotherapy for advanced squamous cell carcinoma of the paranasal sinuses.
Hanna EY, Cardenas AD, DeMonte F, Roberts D, Kupferman M, Weber R, Rosenthal D, Kies M. Hanna EY, et al. Arch Otolaryngol Head Neck Surg. 2011 Jan;137(1):78-81. doi: 10.1001/archoto.2010.231. Arch Otolaryngol Head Neck Surg. 2011. PMID: 21242552
OBJECTIVE: To review the oncologic outcomes in patients with advanced (stage III-IV) squamous cell carcinoma of the paranasal sinuses treated with induction chemotherapy prior to definitive local therapy. ...CONCLUSIONS: Tumor response to induct …
OBJECTIVE: To review the oncologic outcomes in patients with advanced (stage III-IV) squamous cell carcinoma of the …
GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas.
Mazeron JJ, Ardiet JM, Haie-Méder C, Kovács G, Levendag P, Peiffert D, Polo A, Rovirosa A, Strnad V. Mazeron JJ, et al. Radiother Oncol. 2009 May;91(2):150-6. doi: 10.1016/j.radonc.2009.01.005. Epub 2009 Mar 28. Radiother Oncol. 2009. PMID: 19329209 Review.
Both primary and recurrent squamous cell carcinoma of the head and neck are classic indications for brachytherapy. ...The recommendations are then specified for the classical brachytherapy tumor sites following an analogue more focussed structure (pati …
Both primary and recurrent squamous cell carcinoma of the head and neck are classic indications for brachytherap …
Postoperative intensity-modulated radiotherapy in sinonasal carcinoma: clinical results in 39 patients.
Duthoy W, Boterberg T, Claus F, Ost P, Vakaet L, Bral S, Duprez F, Van Landuyt M, Vermeersch H, De Neve W. Duthoy W, et al. Cancer. 2005 Jul 1;104(1):71-82. doi: 10.1002/cncr.21100. Cancer. 2005. PMID: 15915466 Free article. Review.
BACKGROUND: Carcinoma of the paranasal sinuses is rare. Standard therapeutic modalities consist of surgery and radiotherapy (RT). ...METHODS: Between 1998 and 2003, 39 consecutive patients received postoperative irradiation by means of IMRT for an adenocarcin …
BACKGROUND: Carcinoma of the paranasal sinuses is rare. Standard therapeutic modalities consist of surgery and radiothe …
Programmed death ligand-1 expression as immunotherapeutic target in sinonasal cancer.
Riobello C, Vivanco B, Reda S, López-Hernández A, García-Inclán C, Potes-Ares S, Cabal VN, López F, Llorente JL, Hermsen MA. Riobello C, et al. Head Neck. 2018 Apr;40(4):818-827. doi: 10.1002/hed.25067. Epub 2018 Jan 22. Head Neck. 2018. PMID: 29356178
BACKGROUND: Sinonasal cancer carries a poor prognosis, especially in recurrent stages, and it is a disease with very limited treatment options. METHODS: The expression of programmed death ligand-1 (PD-L1) as a marker for immunotherapy was evaluated in 53 sinonasal squam …
BACKGROUND: Sinonasal cancer carries a poor prognosis, especially in recurrent stages, and it is a disease with very limited treatmen …
Radiotherapy as Part of Treatment Strategies in Nasal Cavity and Paranasal Sinus Malignancies.
Owin N, Elsayad K, Rolf D, Haverkamp U, Suwelack D, Tschakert R, Berssenbrugge H, Kleinheinz J, Rudack C, Eich HT. Owin N, et al. Anticancer Res. 2021 Mar;41(3):1587-1592. doi: 10.21873/anticanres.14919. Anticancer Res. 2021. PMID: 33788753
BACKGROUND/AIM: Modern intensity-modulated radiotherapy (IMRT) is frequently applied to treat patients with nasal cavity and paranasal sinus (NC/PNS) malignancies. PATIENTS AND METHODS: One hundred and four patients who underwent radiotherapy (RT) between 1994 and 2 …
BACKGROUND/AIM: Modern intensity-modulated radiotherapy (IMRT) is frequently applied to treat patients with nasal cavity and paranasal …
Radiation with concomitant superselective intra-arterial cisplatin infusion for maxillary sinus squamous cell carcinoma.
Ebara T, Ando K, Eishima J, Suzuki M, Kawakami T, Horikoshi H, Tamaki Y. Ebara T, et al. Jpn J Radiol. 2019 Jun;37(6):494-499. doi: 10.1007/s11604-019-00827-1. Epub 2019 Mar 26. Jpn J Radiol. 2019. PMID: 30915648
PURPOSE: To assess the efficacy and prognostic factors after superselective intra-arterial chemoradiation (RADPLAT) for maxillary sinus squamous cell carcinoma (MS-SCC). MATERIALS AND METHODS: Prognostic significance of age, gender, T and N factors, gr …
PURPOSE: To assess the efficacy and prognostic factors after superselective intra-arterial chemoradiation (RADPLAT) for maxillary sinus …
63 results